OTCM
EVFM
Market cap1mUSD
Oct 08, Last price
0.01USD
1D
0.25%
1Q
-7.06%
IPO
-100.00%
Name
Evofem Biosciences Inc
Chart & performance
P/E
2.68
P/S
0.05
EPS
0.00
Div yield, %
—
Shrs. gr., 5y
1,023.86%
Rev. gr., 5y
114.35%
Revenues
20m
+4.23%
Net income
391k
P
CFO
-2m
L-48.73%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Key people
Justin J. File
Chief Financial Officer · since 2018
Maria Feldman
Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance · since 2016
Kelly Culwell
Chief Medical Officer · since 2018
Alexander A. Fitzpatrick
General Counsel, Secretary · since 2018
Independent Director · since 2018
Legal address
C/O National Corporate Research, Ltd.
850 New Burton Road
Suite 201
Dover, DE 19904
US
850 New Burton Road
Suite 201
Dover, DE 19904
US
Headquarters
9191 Towne Centre Drive
Suite 400
San Diego, CA 92122
US
Suite 400
San Diego, CA 92122
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||